**Telehealth and GLP-1 Agonists: Involving Adolescents with Obesity**

The growing incidence of adolescent obesity, worsened by the COVID-19 pandemic, necessitates creative strategies beyond conventional methods. With 14.4 million children in the U.S. impacted by obesity, along with an increase in related health issues like type 2 diabetes, it is critical to address this health emergency. One promising approach is the use of telehealth models, which have demonstrated potential in involving adolescents and their families in effective obesity management initiatives.

### Telehealth for Obesity Management

Conventional treatment methods for obesity often encounter hurdles, including stigma, logistical issues, and restricted access to specialized care. Telehealth can eliminate these barriers, offering a convenient, stigma-free atmosphere that fosters compliance with treatment plans. An example of this method is Metabolic Telehealth, established in 2022, which provides comprehensive care to children and adolescents across several states. This model encompasses initial assessments, follow-up visits, and the integration of family-based behavioral support, aiming to enhance accessibility and treatment results.

### Efficacy of GLP-1 Agonists

The emergence of GLP-1 agonists, like semaglutide, represents a major breakthrough in the treatment of adolescent obesity. These medications received FDA approval in 2022 for this age group. They function by improving insulin sensitivity and facilitating weight loss. In a study of 44 patients, many experienced significant reductions in BMI as a result of GLP-1 therapy. However, access continues to be problematic due to insurance obstacles and a lack of widespread prescriptions by pediatricians.

### Results and Challenges

Initial findings from the use of telehealth models and GLP-1 treatments are encouraging. The majority of patients in the study managed to achieve significant weight loss and demonstrated enhanced involvement with their treatment plans. Nevertheless, a considerable number of insurance rejections reveal ongoing challenges in the widespread use of GLP-1 medications. Furthermore, although telehealth alleviates some treatment barriers, issues like self-reported vital signs and limited physical evaluations need to be addressed.

### Future Directions

Additional research is necessary to evaluate the long-term impacts of GLP-1 agonists on adolescents, potential ethical considerations, and the formulation of comprehensive strategies to tackle access issues. The integration of telehealth with medical interventions such as GLP-1 agonists offers an effective framework to combat adolescent obesity, but the expansion and refinement of these strategies are vital for achieving the best outcomes.